Congenital myasthenic syndrome (CMS): slow channel

Evidence-based neurology checklist on congenital myasthenic syndrome (cms): slow channel: Pathology This is caused by mutations in the Acetylcholine receptor (AChR) gene The transmission is autosomal dominant Can present in adolescence/later life It is a post synaptic CMS Clinical features…

Pathology

  • This is caused by mutations in the Acetylcholine receptor (AChR) gene
  • The transmission is autosomal dominant
  • Can present in adolescence/later life
  • It is a post synaptic CMS

Clinical features

Treatment

Ineffective treatments

References

  1. Bertorini TE. Neuromuscular Case Studies. Butterworth Heinemann Philadelphia 2008 p454.
  2. Spillane J, Beeson DJ, Kullmann DM. Myasthenia and related disorders of the neuromuscular junction. JNNP 2010; 81:850-857.
  3. Finlayson S, Beeson D, Palace J. Congenital myasthenic syndrome: an update. Pract Neurol 2013; 13:80-91.
  4. Harper CM, Fukodome T, Engel AG. Treatment of slow-channel congenital myasthenic syndrome with fluoxetine. Neurology 2003; 60:1710-1713.
  5. Peyer AK, Abicht A, Heinimann K, Sinnreich M, Fischer D. Quinine sulfate as a therapeutic option in a patient with slow channel congenital myasthenic syndrome. Neuromuscul Disord 2013; 23:571-574. 
  6. And 1 more. Subscribe to see the full list

Related checklists

Loading...